✦ LIBER ✦

Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration

✍ Scribed by Luis Javier Hernández-Pastor; Ana Ortega; Alfredo García-Layana; Joaquín Giráldez

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ranibizumab for retinal angiomatous prol

✍ Timothy Y. Y. Lai; Wai-Man Chan; David T. Liu; Dennis S. Lam 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 205 KB

Cost-effectiveness sequential modeling o

✍ S. Y. Cohen; D. Bremond-Gignac; G. Quentel; G. Mimoun; T. Citterio; S. Bisot-Loc 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 198 KB

Intravitreal anti-VEGF therapy in neovas

✍ C. Zehetner; M. T. Kralinger; G. F. Kieselbach 📂 Article 📅 2008 🏛 Springer Vienna 🌐 German ⚖ 219 KB

Ranibizumab treatment administered as ne

✍ Seungbum Kang; Young-Jung Roh 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 162 KB

Characteristics of eyes with secondary l

✍ Alessandro Mariani; Angeliki Deli; Aude Ambresin; Irmela Mantel 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 291 KB

Subtype lesions of neovascular age-relat

✍ Yan Liu; Feng Wen; Shizhou Huang; Guangwei Luo; Hong Yan; Zuhua Sun; Dezheng Wu 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 216 KB